R
8.22
0.12 (1.48%)
| Previous Close | 8.10 |
| Open | 8.12 |
| Volume | 2,768,945 |
| Avg. Volume (3M) | 2,089,163 |
| Market Cap | 569,104,256 |
| Price / Book | 8.24 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -0.680 |
| Total Debt/Equity (MRQ) | 2.03% |
| Current Ratio (MRQ) | 16.31 |
| Operating Cash Flow (TTM) | -43.54 M |
| Levered Free Cash Flow (TTM) | -25.61 M |
| Return on Assets (TTM) | -34.23% |
| Return on Equity (TTM) | -53.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Regulus Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
-1.4
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -1.38 |
|
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.71% |
| % Held by Institutions | 82.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dafna Capital Management Llc | 31 Mar 2025 | 847,176 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (Canaccord Genuity, 33.82%) | Hold |
| Median | 8.00 (-2.68%) | |
| Low | 7.00 (Jones Trading, -14.84%) | Hold |
| 7.00 (Leerink Partners, -14.84%) | Hold | |
| Average | 8.50 (3.41%) | |
| Total | 4 Hold | |
| Avg. Price @ Call | 7.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 01 May 2025 | 9.00 (9.49%) | Hold | 7.85 |
| 27 Mar 2025 | 6.00 (-27.01%) | Buy | 1.50 | |
| Canaccord Genuity | 30 Apr 2025 | 11.00 (33.82%) | Hold | 7.98 |
| Jones Trading | 30 Apr 2025 | 7.00 (-14.84%) | Hold | 7.98 |
| Leerink Partners | 30 Apr 2025 | 7.00 (-14.84%) | Hold | 7.98 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 May 2025 | Announcement | Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates |
| 30 Apr 2025 | Announcement | Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG |
| 02 Apr 2025 | Announcement | Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit |
| 27 Mar 2025 | Announcement | Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |